123 Atopic Dermatitis Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Atopic Dermatitis Studies in New York

NCT00404898Recruiting

NYU/Bellevue WTC Health Impacts Research Registry

The American Red Cross has funded a multidisciplinary, comprehensive evaluation and treatment program for target individuals with suspected World Trade Center (WTC)-related health problems. The popula...

New York, NY40,000 participantsNYU Langone Health

View Study Details

NCT04194138Recruiting

Complex Adult Deformity Surgery (CADS)

Evaluate surgical treatment outcomes and identify best practice guidelines for complex adult spinal deformity (ASD) patients, including radiographic and clinical outcomes, surgical and postoperative c...

New York, NY1,500 participantsInternational Spine Study Group Foundation

View Study Details

NCT06963723Recruiting

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, i...

New York, NYNA1,000 participantsAlliance Foundation Trials, LLC.

View Study Details

NCT07070232Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in particip...

New York, NYPHASE1980 participantsBioNTech SE

View Study Details

NCT06172478Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

New York, NYPHASE2740 participantsDaiichi Sankyo

View Study Details

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

New York, NYPHASE1695 participantsAstraZeneca

View Study Details

NCT05867420Recruiting

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patient...

New York, NYPHASE1594 participantsAskGene Pharma, Inc.

View Study Details

NCT07084441Recruiting

Comparison of Outcomes of Management of Bowel Obstruction

The Comparison of Outcomes of Management of Bowel Obstruction (COMBO) trial is a patient-level randomized trial of a short course of dexamethasone + supportive care vs supportive care alone for patien...

New York, NYPHASE4550 participantsUniversity of Washington

View Study Details

NCT05584670Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

New York, NYPHASE1542 participantsSanofi

View Study Details

NCT06703476Recruiting

A Study of Surgical Techniques During Cystectomy

The purpose of this study is to look at two standard surgical techniques used during a radical cystectomy and see whether they influence outcomes such as length of stay in the hospital and infections ...

New York, NYPHASE3530 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06350539Recruiting

Personalized Models for Cancer Research

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will hel...

New York, NY500 participantsNew York Stem Cell Foundation Research Institute

View Study Details

NCT03781752Recruiting

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes an...

New York, NYPHASE4500 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT05932862Recruiting

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of ...

New York, NYPHASE1429 participantsExelixis

View Study Details

NCT06662500Recruiting

FORWARD CAD IDE Study

The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithot...

New York, NYNA408 participantsShockwave Medical, Inc.

View Study Details

NCT07037901Recruiting

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo....

New York, NYPHASE2405 participantsInmagene LLC

View Study Details

NCT04515810Recruiting

Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning

This clinical trial tests a new mobile health application (app) called Planning Advance Care Together (PACT) to help people with cancer talk about and plan for advance care planning (the care they wou...

New York, NYNA400 participantsFred Hutchinson Cancer Center

View Study Details

NCT06932081Recruiting

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigati...

New York, NY400 participantsLeiden University Medical Center

View Study Details

NCT05721937Recruiting

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: * Are currently or recently ...

New York, NY400 participantsPfizer

View Study Details

NCT06625775Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced...

New York, NYPHASE1392 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT06998407Recruiting

Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in pat...

New York, NYPHASE1380 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT05592626Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with ad...

New York, NYPHASE1365 participantsMarengo Therapeutics, Inc.

View Study Details

NCT05824975Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembro...

New York, NYPHASE1358 participantsGI Innovation, Inc.

View Study Details

NCT07318402Recruiting

Operator Radiation Exposure During Image-Guided Robotic-Assisted Bronchoscopy: A Multicenter Prospective Cohort Study

This is a multicenter, single-arm, prospective, observational study designed to evaluate bronchoscopist radiation exposure during standard-of-care image-guided robotic-assisted bronchoscopy (RAB) for ...

New York, NY350 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05053230Recruiting

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body program...

New York, NYNA324 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04977453Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab, lenvatinib or lo...

New York, NYPHASE1317 participantsGI Innovation, Inc.

View Study Details

NCT05434234Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) follo...

New York, NYPHASE1312 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT04429542Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergis...

New York, NYPHASE1292 participantsBicara Therapeutics

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

New York, NYPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT07408310Recruiting

Trial of Spiritual Care Interventions for Patients With Cancer

This study aims to determine the effects of 2 spiritual care interventions. Spiritual wellness and healthcare service utilization will be measured from a sample of advanced cancer patients recruited f...

New York, NYNA288 participantsWeill Medical College of Cornell University

View Study Details

NCT06042699Recruiting

Kids With Iron Deficiency and Scoliosis

This study is a randomized controlled trial of preoperative oral iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood c...

New York, NYNA275 participantsColumbia University

View Study Details

NCT07277413Recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with met...

New York, NYPHASE1260 participantsIDEAYA Biosciences

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

New York, NYPHASE1254 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06657222Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...

New York, NYPHASE1250 participantsTubulis GmbH

View Study Details

NCT06031441Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti...

New York, NYPHASE1250 participantsGenentech, Inc.

View Study Details

NCT04145622Recruiting

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. Th...

New York, NYPHASE1250 participantsDaiichi Sankyo

View Study Details

NCT07186842Recruiting

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how ...

New York, NYPHASE1245 participantsBioNTech SE

View Study Details

NCT03556228Recruiting

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have p...

New York, NYPHASE1242 participantsVM Oncology, LLC

View Study Details

NCT06808477Recruiting

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate t...

New York, NYPHASE1237 participantsBambusa Therapeutics

View Study Details

NCT05033028Recruiting

Smartphones for Opiate Addiction Recovery

Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use du...

New York, NYPHASE3225 participantsNYU Langone Health

View Study Details

NCT05719558Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The main aims of this study are: * To check the safety of ASP1002 in people with certain solid tumors. * To check if the people can tolerate ASP1002. * To find a suitable dose of ASP1002. This study ...

New York, NYPHASE1210 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06060613Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors....

New York, NYPHASE1208 participantsObsidian Therapeutics, Inc.

View Study Details

NCT05398484Recruiting

Psilocybin Therapy in Advanced Cancer

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existent...

New York, NYPHASE2200 participantsNYU Langone Health

View Study Details

NCT06051890Recruiting

Assessing Optimal XRB Initiation Points in Jail

This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Cor...

New York, NYPHASE4200 participantsNYU Langone Health

View Study Details

NCT03483337Recruiting

New MRI Biomarkers in Head and Neck Cancers

Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. This makes specific organs, blood ves...

New York, NY200 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05902988Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

New York, NYPHASE1200 participantsVolastra Therapeutics, Inc.

View Study Details

NCT04752826Recruiting

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed...

New York, NYPHASE1176 participantsBioInvent International AB

View Study Details

NCT05270213Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endo...

New York, NYPHASE1164 participantsRiboscience, LLC.

View Study Details

NCT06469944Recruiting

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...

New York, NYPHASE1160 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07262619Recruiting

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combinat...

New York, NYPHASE1160 participantsEikon Therapeutics

View Study Details

NCT06600321Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended d...

New York, NYPHASE1158 participantsAlnylam Pharmaceuticals

View Study Details

NCT06899204Recruiting

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who ha...

New York, NY150 participantsPfizer

View Study Details

NCT07020117Recruiting

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advan...

New York, NYPHASE1150 participantsAktis Oncology, Inc.

View Study Details

NCT07228247Recruiting

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors...

New York, NYPHASE1147 participantsHutchmed

View Study Details

NCT06781983Recruiting

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanc...

New York, NYPHASE1145 participantsInnate Pharma

View Study Details

NCT04775485Recruiting

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying ...

New York, NYPHASE2141 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06698003Recruiting

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for th...

New York, NYPHASE2134 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07535112Recruiting

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS. Colorectal canc...

New York, NYPHASE1130 participantsBayer

View Study Details

NCT06533761Recruiting

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor effi...

New York, NYPHASE1125 participantsStelexis BioSciences

View Study Details

NCT06496750Recruiting

Ketamine for Methamphetamine Use Disorder

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week rando...

New York, NYPHASE2120 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT05929235Recruiting

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question\[s\] it aims to answer are: * Is FX-9...

New York, NYPHASE1120 participantsFlare Therapeutics Inc.

View Study Details

NCT06395519Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

New York, NYPHASE1120 participants858 Therapeutics, Inc.

View Study Details

NCT07080242Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroen...

New York, NYPHASE1120 participantsSystImmune Inc.

View Study Details

NCT07644039Recruiting

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembr...

New York, NYPHASE1119 participantsPharmaMar

View Study Details

NCT06425926Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...

New York, NYPHASE1117 participantsGeorgiamune Inc

View Study Details

NCT06462183Recruiting

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC...

New York, NYPHASE1105 participantsRgenta Therapeutics Inc

View Study Details

NCT05952934Recruiting

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in term...

New York, NYPHASE2100 participantsUniversity of Arkansas

View Study Details

NCT06716138Recruiting

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, a...

New York, NYPHASE196 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT07282587Recruiting

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG)....

New York, NYPHASE290 participantsJazz Pharmaceuticals

View Study Details

NCT06504160Recruiting

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatm...

New York, NYPHASE186 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT05798897Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starti...

New York, NYPHASE179 participantsMarker Therapeutics, Inc.

View Study Details

NCT07166601Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looki...

New York, NYPHASE177 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT05004116Recruiting

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumo...

New York, NYPHASE177 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05551793Recruiting

Regeneron AA Multicenter (Dupilumab)

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affe...

New York, NYPHASE276 participantsEmma Guttman

View Study Details

NCT05932680Recruiting

Limited-duration Teclistamab

This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria...

New York, NYPHASE275 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT05886920Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with ad...

New York, NYPHASE167 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT06307795Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...

New York, NYPHASE163 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT05269316Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors...

New York, NYPHASE161 participantsImpact Therapeutics, Inc.

View Study Details

NCT06503614Recruiting

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS)...

New York, NYPHASE260 participantsJohn Sfakianos

View Study Details

NCT07242638Recruiting

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata...

New York, NYPHASE256 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT05126472Recruiting

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove ...

New York, NYPHASE155 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04890613Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid t...

New York, NYPHASE152 participantsSenhwa Biosciences, Inc.

View Study Details

NCT06126744Recruiting

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, administered intratumorally by convection-enhan...

New York, NYPHASE151 participantsDuke University

View Study Details

NCT05719935Recruiting

The KinematX Midcarpal Total Wrist Arthroplasty Registry

The goal of this observational study is to learn about functional and patient reported outcomes in patient undergoing total wrist replacement with the KinematX total wrist replacement study. The main...

New York, NY50 participantsExtremity Medical

View Study Details

NCT06809140Recruiting

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and cystoscopy with TURBT of any...

New York, NYPHASE247 participantsMatthew Galsky

View Study Details

NCT04458545Recruiting

Clinical Trials of Multivalent Opioid Vaccine Components

Currently, abuse of prescription opioid analgesics and heroin is a serious problem in the U.S. Although several medications, including methadone, buprenorphine, and naltrexone, are available and effec...

New York, NYPHASE145 participantsNew York State Psychiatric Institute

View Study Details

NCT07063212Recruiting

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck ...

New York, NYPHASE240 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06829173Recruiting

Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O...

New York, NYEARLY_PHASE139 participantsNYU Langone Health

View Study Details

NCT05219695Recruiting

Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)

The objective of this study is to demonstrate the initial clinical feasibility of using Harmonic Motion Imaging (HMI) for Focused Ultrasound Surgery (FUS) guidance and monitoring in patients with beni...

New York, NYNA36 participantsColumbia University

View Study Details

NCT07584226Recruiting

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, a...

New York, NYPHASE135 participantsRelay Therapeutics, Inc.

View Study Details

NCT06891560Recruiting

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC)....

New York, NYPHASE234 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05487170Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous ...

New York, NYPHASE132 participantsRanok Therapeutics (Hangzhou) Co., Ltd.

View Study Details

NCT07156565Recruiting

Actinium Therapy for Late-stage Aggressive Sarcomas

The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2...

New York, NYPHASE130 participantsRatio Therapeutics, Inc.

View Study Details

NCT03718936Recruiting

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

ADNP, also known as Activity Dependent Neuroprotective Protein, is a rare neurodevelopmental disorder caused by mutations encompassing the ADNP gene on chromosome 20. Clinically, ADNP syndrome is char...

New York, NY30 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT06340711Recruiting

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cance...

New York, NYPHASE227 participantsWeill Medical College of Cornell University

View Study Details

NCT07024615Recruiting

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell ...

New York, NYPHASE125 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT05239624Recruiting

Enfortumab Vedotin and Pembrolizumab in People with Bladder Cancer

This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to h...

New York, NYPHASE223 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07405645Recruiting

Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy

This phase 1 multi-site study investigates the safety and initial effectiveness of focused ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain associated with hea...

New York, NYNA20 participantsUniversity of Virginia

View Study Details

NCT05562791Recruiting

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers wa...

New York, NYPHASE120 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06066333Recruiting

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortic...

New York, NYPHASE212 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05544136Recruiting

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will...

New York, NYPHASE212 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07216521Recruiting

Intent of Surgery for IPMN

This multicenter retrospective observational cohort study seeks to: 1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion o...

New York, NY2,000 participantsNYU Langone Health

View Study Details

NCT05677880Recruiting

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled...

New York, NY660 participantsUniversity of Wisconsin, Madison

View Study Details

NCT04278690Recruiting

Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit

This is a randomized controlled study of parents of children to be discharged from the neonatal intensive care unit at Bellevue and Elmhurst hospitals. A total of 425 subjects will be recruited across...

New York, NYNA425 participantsNYU Langone Health

View Study Details

NCT06792552Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors...

New York, NYPHASE1414 participantsNextCure, Inc.

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

New York, NYPHASE1351 participantsFate Therapeutics

View Study Details

NCT07032506Recruiting

Intrauterine Stent Placement Following Hysteroscopic Septum Resection

The study hopes to learn the best way to prevent internal scar tissue after septum removal. The use of an intrauterine foley catheter balloon may prevent the formation of adhesions following surgery....

New York, NYNA320 participantsWeill Medical College of Cornell University

View Study Details

NCT06030011Recruiting

Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early...

New York, NYNA270 participantsThe University of Texas Health Science Center, Houston

View Study Details

NCT04888104Recruiting

Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients

Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients...

New York, NY225 participantsInternational Spine Study Group Foundation

View Study Details

NCT06859762Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors...

New York, NYPHASE1220 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT04906434Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

This is an open-label phase 1 study with an escalation part and an expansion part....

New York, NYPHASE1200 participantsAbbisko Therapeutics Co, Ltd

View Study Details

NCT06123481Recruiting

Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis

Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. ...

New York, NYNA192 participantsJohns Hopkins University

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

New York, NYPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT02507141Recruiting

Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology

The purpose of this study is to get images (pictures) of oral lesions, which occur inside the mouth, before the patient's surgery using a special camera. These pictures will be used in our research to...

New York, NY140 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05873686Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected...

New York, NYPHASE1140 participantsNuvectis Pharma, Inc.

View Study Details

NCT06118086Recruiting

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)...

New York, NYPHASE1125 participantsRemix Therapeutics

View Study Details

NCT07212166Recruiting

A Study of Questionnaires in Adolescents and Young Adults With Cancer

The purpose of this study is to evaluate a questionnaire called PRO-AYA: Patient-Reported Outcomes for Adolescents and Young Adults....

New York, NY120 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07361562Recruiting

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity ...

New York, NYPHASE1100 participantsCogent Biosciences, Inc.

View Study Details

NCT05617495Recruiting

Mindfulness-Based fMRI Neurofeedback for Depression

In the United States, adolescents experience alarmingly high rates of major depression, and gold-standard treatments are only effective for approximately half of patients. Rumination may be a promisin...

New York, NYNA90 participantsColumbia University

View Study Details

NCT07607678Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and together with ...

New York, NYPHASE160 participantsBoehringer Ingelheim

View Study Details

NCT05207098Recruiting

A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy

The researchers are doing this study to collect more information about if, and how, neurocognitive function may be affected in people being treated with radiation therapy for head and neck cancer. Par...

New York, NY60 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07189403Recruiting

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC....

New York, NYPHASE140 participantsDaiichi Sankyo

View Study Details

NCT07540221Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein...

New York, NYPHASE340 participantsGrifols Therapeutics LLC

View Study Details

NCT04997993Recruiting

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Leflunomide in patients with PTEN-Altered advanced solid tumors or HER2 negative breast cancer. Phase 1A objectives are to determine the safety, tolerability, and the MTD of leflunomide in patients wi...

New York, NYPHASE123 participantsDeborah Doroshow

View Study Details

About Atopic Dermatitis Clinical Trials in New York

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 123 atopic dermatitis clinical trials recruiting participants in New York, NY. These studies are seeking a combined 68,856 participants. Research is being sponsored by NYU Langone Health, International Spine Study Group Foundation, Alliance Foundation Trials, LLC. and 83 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in New York — FAQ

Are there atopic dermatitis clinical trials in New York?

Yes, there are 123 atopic dermatitis clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 123 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated July 20, 2026 from ClinicalTrials.gov